Intravenous iron to treat anaemia before cardiac surgery (ITACS): international, double blind, placebo controlled randomised trial
Source: View publication →
In patients with anaemia awaiting elective cardiac surgery, a single preoperative dose of intravenous iron slightly increased the number of days alive and at home within 90 days and significantly reduced red blood cell transfusion requirements compared to placebo.
Key Findings
Study Design
Study Limitations
Clinical Significance
ITACS establishes preoperative intravenous iron as a beneficial patient blood management strategy for anaemic patients undergoing elective cardiac surgery, demonstrating clear reductions in red cell transfusions and modest, though statistically significant, gains in patient-centered recovery metrics.
Historical Context
Preoperative anaemia affects approximately 30% of patients undergoing cardiac surgery and is a major independent risk factor for perioperative blood transfusions, prolonged hospital stays, and increased mortality. Prior to the ITACS trial, smaller studies and meta-analyses indicated that preoperative IV iron could improve hemoglobin and reduce transfusion rates, but these studies were underpowered to demonstrate improvements in broader, patient-centered clinical outcomes. ITACS was designed as a large, definitive, pragmatic trial to evaluate whether preoperative IV iron not only restores hemoglobin but also meaningfully accelerates functional recovery and time spent out of the hospital.
Guided Discussion
High-yield insights from every perspective
Why is intravenous iron preferred over oral iron for treating anemia in the immediate preoperative period for elective cardiac surgery?
Key Response
Oral iron takes weeks to months to correct anemia, has poor gastrointestinal absorption (especially in inflammatory states due to increased hepcidin levels), and frequently causes gastrointestinal side effects leading to poor compliance. Intravenous iron bypasses gut absorption, rapidly providing a large dose directly to the reticuloendothelial system for immediate erythropoiesis, which is crucial when surgery is scheduled in a short timeframe.
When evaluating a patient for elective cardiac surgery who has preoperative anemia, what laboratory markers differentiate absolute iron deficiency from anemia of chronic disease, and how does the ITACS trial influence the decision to treat with IV iron?
Key Response
Residents should check a CBC, ferritin, and transferrin saturation (TSAT). Absolute iron deficiency typically presents with ferritin less than 30-50 ng/mL, while anemia of chronic disease may show normal or elevated ferritin but a low TSAT (less than 20 percent). The ITACS trial suggests that giving a single dose of IV iron to anemic patients preoperatively reduces the need for RBC transfusions regardless of the specific anemia etiology, simplifying the preoperative management pathway.
Given that maximal hemoglobin response to intravenous iron typically takes 2 to 4 weeks, how might IV iron administration shortly before surgery confer benefits beyond simple erythropoiesis?
Key Response
While the timeframe before surgery may be too short for a substantial rise in circulating hemoglobin, iron is also a critical component of myoglobin and mitochondrial enzymes (such as cytochromes). Fellows should consider that early clinical benefits, including improved functional capacity and tolerance to cardiopulmonary bypass, might stem from enhanced cellular respiration and reduced tissue ischemia at the mitochondrial level before macro-level erythropoiesis occurs.
The ITACS trial demonstrated a significant reduction in RBC transfusions but only a marginal improvement in days alive and at home (DAAH). How should surgical and anesthesia directors weigh the economic value of reduced transfusions against the logistical costs of establishing a routine preoperative IV iron clinic?
Key Response
Attendings must balance clinical outcomes with institutional resource allocation. While the primary DAAH endpoint showed modest gains, reducing RBC transfusions decreases alloimmunization risks, volume overload, and blood bank utilization. The logistics of a pre-op anemia clinic require nursing time, physical space, and drug costs; however, avoiding even one or two units of transfused blood per patient often creates a compelling cost-effectiveness argument for institutional adoption of preoperative IV iron protocols.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
The ITACS trial utilized 'Days Alive and at Home' (DAAH) within 90 days as its primary outcome. What are the methodological advantages and statistical challenges of using DAAH as a composite endpoint in perioperative trials compared to traditional time-to-event mortality endpoints?
Key Response
DAAH is a highly patient-centered metric that integrates mortality, length of stay, and readmissions into a single continuous or ordinal variable, increasing statistical power and avoiding the massive sample sizes required for mortality-only trials. However, DAAH is highly prone to skewed, non-normal distributions (ceiling effects where most patients have high DAAH), which requires complex non-parametric statistics or zero-inflated modeling, potentially complicating the clinical interpretation of the effect size.
Intravenous iron preparations are notoriously difficult to blind because they are distinctively dark brown compared to clear saline placebos. How does the potential failure of blinding in the preoperative clinic threaten the internal validity of this trial, particularly regarding transfusion thresholds?
Key Response
If patients, anesthesiologists, or surgeons become unblinded due to the visual difference of the infusion, it introduces high risk for performance and detection bias. A clinician aware that a patient received placebo might have a lower, more conservative threshold to transfuse (violating standardized protocol triggers) or may keep the patient longer in the hospital, directly skewing both the secondary transfusion endpoint and the primary DAAH endpoint. Rigorous editorial review demands explicit details on how blinding (e.g., using opaque bags and dark tubing) was strictly maintained.
Current Patient Blood Management guidelines from societies like the Society of Thoracic Surgeons strongly recommend screening for and treating preoperative anemia, but often suggest delaying surgery to allow for oral or IV iron efficacy. Based on the ITACS data, should guidelines upgrade recommendations for routine single-dose IV iron even when the surgical window is very short?
Key Response
The ITACS trial provides high-quality randomized evidence that a single preoperative dose of IV iron significantly reduces transfusion requirements, even without a long lead time before surgery. Guideline committees should consider updating their pathways to explicitly recommend single-dose IV iron administration in the short preoperative window, shifting the paradigm away from necessarily delaying surgery for anemia optimization, thereby strengthening Grade 1 recommendations for preoperative Patient Blood Management.
Clinical Landscape
Noteworthy Related Trials
FAIR-HF Trial
Tested
Intravenous ferric carboxymaltose
Population
Patients with chronic heart failure and iron deficiency
Comparator
Placebo
Endpoint
Self-reported Patient Global Assessment and NYHA functional class
TRICS III Trial
Tested
Restrictive red-cell transfusion threshold
Population
Adults undergoing cardiac surgery with moderate-to-high risk of death
Comparator
Liberal red-cell transfusion threshold
Endpoint
Composite of death, myocardial infarction, stroke, or new-onset renal failure
PREVENTT Trial
Tested
Intravenous ferric carboxymaltose
Population
Adults with anaemia undergoing major open abdominal surgery
Comparator
Placebo
Endpoint
Composite of death or blood transfusion within 30 days postoperatively
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis